| Browse All

Connect Biopharma Holdings Limited (CNTB)

Healthcare | Biotechnology | San Diego, United States | NasdaqGM
2.68 USD -0.13 (-4.626%) ⇩ (April 20, 2026, 4 p.m. EDT)

Short-term: ★★★★☆ | Long-term: ★★★★☆ | Dividends: ★★★★★
Hot Take | April 18, 2026, 10:24 p.m. EDT

Despite the massive cash raise and insider accumulation, the lack of dividend growth and negative EA/Share growth masks a significant value pivot here; CNTB is effectively being bought purely on clinical catalysts and the de-risking of its cash balance sheet, making it a solid 'Hamster Wheel' high-beta hold (4 stars) rather than a deep value play (0 on fundamental growth due to negative figures), though the yield is technically infinite due to the lack of payouts to deleverage the balance sheet.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.063643
MSTL0.071173
AutoETS0.073458
AutoARIMA0.132611

Forecast horizon: 45 days | Selected: AutoTheta

Forecast Reliability
Score 57%
H-stat 1.36
Ljung-Box p 0.030
Jarque-Bera p 0.000
Excess Kurtosis 2.15
Attribute Value
Sector Healthcare
Debt to Equity Ratio 1.644
Revenue per Share 0.001
Market Cap 151,477,040
Forward P/E -3.59
Website https://www.connectbiopharm.com

As of April 18, 2026, 10:24 p.m. EDT: The options market shows a distinct bullish bias in speculative positioning. For the near-term expiration (04-17), despite the low implied volatility environment (ATM IV ~5%), there is a massive volume of calls traded at the current price (ATM) compared to puts, suggesting immediate bets on upside momentum. Conversely, put volume is almost entirely confined to OTM strikes lower than current price, acting as a hedge for downside rather than an expression of imminent crash expectations. The IV crush suggests the market expects a static price, but the flow imbalance favors upside.


Info Dump

Attribute Value
52 Week Change 2.8285713
Address1 3,580 CARMEL MOUNTAIN ROAD
Address2 SUITE 200
All Time High 29.274
All Time Low 0.51
Ask 2.7
Ask Size 2
Average Analyst Rating 1.0 - Strong Buy
Average Daily Volume10 Day 379,530
Average Daily Volume3 Month 236,747
Average Volume 236,747
Average Volume10Days 379,530
Bid 2.62
Bid Size 1
Book Value 0.744
City San Diego
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 2.68
Current Ratio 3.741
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 3.0299
Day Low 2.61
Debt To Equity 1.644
Display Name Connect Biopharma
Earnings Timestamp End 1,758,283,200
Earnings Timestamp Start 1,757,069,940
Ebitda -57,370,000
Ebitda Margins 0.0
Enterprise To Ebitda -1.879
Enterprise To Revenue 1,684.766
Enterprise Value 107,825,032
Eps Current Year -0.8675
Eps Forward -0.7475
Eps Trailing Twelve Months -1.0
Esg Populated 0
Exchange NGM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 2.7746
Fifty Day Average Change -0.09459996
Fifty Day Average Change Percent -0.03409499
Fifty Two Week Change Percent 282.85712
Fifty Two Week High 3.82
Fifty Two Week High Change -1.1399999
Fifty Two Week High Change Percent -0.29842928
Fifty Two Week Low 0.65
Fifty Two Week Low Change 2.0300002
Fifty Two Week Low Change Percent 3.1230774
Fifty Two Week Range 0.65 - 3.82
Financial Currency USD
First Trade Date Milliseconds 1,616,160,600,000
Float Shares 12,027,729
Forward Eps -0.7475
Forward P E -3.5852845
Free Cashflow -30,651,250
Full Exchange Name NasdaqGM
Full Time Employees 64
Gmt Off Set Milliseconds -14,400,000
Gross Margins 1.0
Gross Profits 64,000
Has Pre Post Market Data 1
Held Percent Insiders 0.3806
Held Percent Institutions 0.52975
Implied Shares Outstanding 56,521,282
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,021-03-19
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.
Long Name Connect Biopharma Holdings Limited
Market us_market
Market Cap 151,477,040
Market State PRE
Max Age 86,400
Message Board Id finmb_706016439
Most Recent Quarter 1,767,139,200
Net Income To Common -55,480,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 151,477,035
Number Of Analyst Opinions 5
Open 2.8
Operating Cashflow -51,206,000
Operating Margins -907.40625
Payout Ratio 0.0
Phone 858 727 1040
Pre Market Change 0.14999986
Pre Market Change Percent 5.5970097
Pre Market Price 2.83
Pre Market Time 1,776,770,909
Previous Close 2.81
Price Eps Current Year -3.089337
Price Hint 4
Price To Book 3.6021504
Price To Sales Trailing12 Months 2,366.8289
Profit Margins 0.0
Quick Ratio 3.269
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.0
Region US
Regular Market Change -0.13
Regular Market Change Percent -4.62633
Regular Market Day High 3.0299
Regular Market Day Low 2.61
Regular Market Day Range 2.61 - 3.0299
Regular Market Open 2.8
Regular Market Previous Close 2.81
Regular Market Price 2.68
Regular Market Time 1,776,715,201
Regular Market Volume 416,150
Return On Assets -0.46132
Return On Equity -0.82716006
Revenue Growth -1.0
Revenue Per Share 0.001
Sand P52 Week Change 0.34445214
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 56,521,282
Shares Percent Shares Out 0.0106
Shares Short 601,458
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 304,407
Short Name Connect Biopharma Holdings Limi
Short Percent Of Float 0.015800001
Short Ratio 2.19
Source Interval 15
State CA
Symbol CNTB
Target High Price 10.0
Target Low Price 6.0
Target Mean Price 7.9
Target Median Price 7.5
Total Cash 44,342,000
Total Cash Per Share 0.785
Total Debt 690,000
Total Revenue 64,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -1.0
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 2.21802
Two Hundred Day Average Change 0.4619801
Two Hundred Day Average Change Percent 0.20828491
Type Disp Equity
Volume 416,150
Website https://www.connectbiopharm.com
Zip 92,130